Medicare beneficiaries enrolled in the traditional fee-for-service program now face a new requirement before receiving certain knee and spine procedures. The Centers for Medicare and Medicaid Services has begun testing prior authorization for services it considers wasteful or inappropriate, starting with knee arthroscopy for osteoarthritis, electrical nerve stimulator implants, and skin and tissue substitutes. The program, called the Wasteful and Inappropriate Service Reduction model, or WISeR, pairs artificial intelligence and machine learning screening with clinician review to flag claims before procedures are performed.
How the WISeR model changes access to knee scopes and spinal injections
Traditional Medicare has long operated without the prior authorization gates that commercial insurers and Medicare Advantage plans routinely impose. The WISeR model breaks that pattern by requiring fee-for-service beneficiaries and their providers to obtain advance approval for specific procedures. CMS designed the pilot to target wasteful services while preserving access to care that meets evidence-based standards.
For knee arthroscopy, the model applies the existing coverage restrictions spelled out in the national policy for arthroscopic procedures, which already limits arthroscopic lavage and debridement when osteoarthritis is the primary diagnosis. That policy has been on the books for years, yet utilization of these procedures has persisted in certain regions. Adding a prior authorization layer on top of that existing restriction could accelerate the decline in knee arthroscopy volumes beyond what the coverage determination alone has achieved, because providers must now document compliance before the procedure rather than face retrospective audits afterward.
Spinal injections tell a different story. Epidural steroid injections for back pain already operate under tighter guardrails through local coverage rules such as L39015 guidance, which sets documentation requirements, frequency limits, and medical necessity criteria. Facet joint interventions follow a parallel set of rules under related local determinations that spell out indications, imaging expectations, and caps on repeat procedures. Because these policies already impose preprocedure documentation standards and frequency edits, the added friction of prior authorization may produce a smaller change in injection volumes compared to knee arthroscopy, where enforcement has historically relied more on after-the-fact review.
Coverage rules and AI screening behind the pilot
The WISeR model sits within the CMS Innovation Center, known as CMMI, which tests payment and delivery reforms under authority granted by statute. The model’s official materials describe how AI and machine learning tools screen incoming prior authorization requests, comparing clinical details in the submission against established coverage criteria. Requests that clearly meet the rules may be auto-approved, while those that fall outside or lack key documentation are flagged for human review.
A clinician then reviews flagged requests before a final determination is issued. CMS has stated that the process is meant to reduce inappropriate procedures without blocking care that meets medical necessity standards. In practice, this means providers must supply operative notes, imaging reports, and prior treatment histories that demonstrate why the requested service is reasonable and necessary for the individual patient.
The coverage criteria themselves are not new. National policy for knee arthroscopy already limits use in patients whose primary problem is degenerative osteoarthritis rather than a discrete mechanical lesion such as a meniscal tear. For spinal injections, local determinations specify conservative therapies that should be tried first, define the types of pain patterns that qualify, and cap the number of injections allowed within a given time frame. WISeR does not rewrite those rules; instead, it moves enforcement to the front end of the care pathway.
Implications for patients and clinicians
For patients, the most visible change is timing. Under retrospective review, a procedure might proceed as scheduled, with payment disputes surfacing months later. Under WISeR, the key question is answered before the procedure date: Will Medicare pay for this service given the documented clinical picture? This can prevent surprise bills tied to denied claims, but it may also delay care if documentation is incomplete or if requests require multiple rounds of clarification.
Clinicians, meanwhile, must adapt workflows. Practices that perform large volumes of knee arthroscopies or spinal injections will need staff trained to assemble and submit prior authorization packets that align with the relevant national and local coverage rules. Electronic health record templates may need to be updated so that required elements-such as duration of symptoms, functional limitations, prior therapies, and imaging findings-are captured in a structured way that supports rapid review.
The model also raises questions about algorithmic transparency and appeal rights. While CMS emphasizes that clinicians make the final decisions, the AI tools determine which cases appear straightforward and which are scrutinized more closely. Providers may want to understand how borderline cases are categorized and what data elements most strongly influence automated flags. Clear, timely appeal pathways will be critical for patients whose requests are initially denied despite meeting clinical expectations.
What to watch as WISeR rolls out
As WISeR progresses, observers will be watching several indicators: changes in utilization rates for targeted procedures, regional variation in approval and denial patterns, and any measurable shifts in patient outcomes such as pain control, function, or complication rates. Another key question is administrative burden-whether the model streamlines review compared with older, manual processes, or whether it adds new layers of paperwork for practices already stretched thin.
If WISeR demonstrates that AI-supported prior authorization can trim low-value care without harming access, CMS could expand the model to additional services or geographic areas. Conversely, if denials cluster in ways that suggest underuse of necessary care, or if appeals overwhelm the system, policymakers may need to recalibrate the balance between cost control and timely treatment. For now, patients considering knee arthroscopy or spinal injections under traditional Medicare should expect more front-end review and closer alignment with written coverage criteria than in years past.
